EP1037632B1
(de)
|
1997-11-10 |
2006-01-11 |
Bristol-Myers Squibb Company |
Benzothiazole als protein tyrosin-kinase inhibitoren
|
AU5438499A
(en)
|
1998-08-29 |
2000-03-21 |
Astrazeneca Ab |
Pyrimidine compounds
|
ES2274634T3
(es)
|
1998-08-29 |
2007-05-16 |
Astrazeneca Ab |
Compuestos de pirimidina.
|
GB9828511D0
(en)
|
1998-12-24 |
1999-02-17 |
Zeneca Ltd |
Chemical compounds
|
GB9905075D0
(en)
|
1999-03-06 |
1999-04-28 |
Zeneca Ltd |
Chemical compounds
|
GB9907658D0
(en)
|
1999-04-06 |
1999-05-26 |
Zeneca Ltd |
Chemical compounds
|
PL215901B1
(pl)
|
1999-04-15 |
2014-02-28 |
Bristol Myers Squibb Co |
Cykliczny inhibitor bialkowych kinaz tyrozynowych, jego zastosowanie oraz kompozycja farmaceutyczna zawierajaca taki zwiazek
|
US7125875B2
(en)
|
1999-04-15 |
2006-10-24 |
Bristol-Myers Squibb Company |
Cyclic protein tyrosine kinase inhibitors
|
DE60017898T2
(de)
*
|
1999-06-09 |
2006-01-12 |
Yamanouchi Pharmaceutical Co., Ltd. |
Neuartige heterocyclische carboxamidderivate
|
AU5108000A
(en)
*
|
1999-06-10 |
2001-01-02 |
Yamanouchi Pharmaceutical Co., Ltd. |
Novel nitrogen-contaiing heterocyclic derivatives or salts thereof
|
GB9914258D0
(en)
*
|
1999-06-18 |
1999-08-18 |
Celltech Therapeutics Ltd |
Chemical compounds
|
GB9919778D0
(en)
|
1999-08-21 |
1999-10-27 |
Zeneca Ltd |
Chemical compounds
|
JP2003511378A
(ja)
|
1999-10-07 |
2003-03-25 |
アムジエン・インコーポレーテツド |
トリアジン系キナーゼ阻害薬
|
EP1223170B1
(de)
*
|
1999-10-12 |
2005-12-28 |
Takeda Pharmaceutical Company Limited |
Pyrimidin-5-carboximidverbindungen, verfahren zur herstellung derselben und deren verwendung
|
AU1941501A
(en)
*
|
1999-11-30 |
2001-06-12 |
Parker Hughes Institute |
Syk localized at centrosome
|
CN1429222A
(zh)
|
2000-02-17 |
2003-07-09 |
安姆根有限公司 |
激酶抑制剂
|
GB0004888D0
(en)
|
2000-03-01 |
2000-04-19 |
Astrazeneca Uk Ltd |
Chemical compounds
|
GB0004886D0
(en)
|
2000-03-01 |
2000-04-19 |
Astrazeneca Uk Ltd |
Chemical compounds
|
GB0004890D0
(en)
|
2000-03-01 |
2000-04-19 |
Astrazeneca Uk Ltd |
Chemical compounds
|
GB0004887D0
(en)
|
2000-03-01 |
2000-04-19 |
Astrazeneca Uk Ltd |
Chemical compounds
|
GB0007371D0
(en)
|
2000-03-28 |
2000-05-17 |
Astrazeneca Uk Ltd |
Chemical compounds
|
CN1440393A
(zh)
*
|
2000-04-28 |
2003-09-03 |
田边制药株式会社 |
环状化合物
|
JP2001302667A
(ja)
*
|
2000-04-28 |
2001-10-31 |
Bayer Ag |
イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体
|
US7273868B2
(en)
*
|
2000-04-28 |
2007-09-25 |
Tanabe Seiyaku Co., Ltd. |
Pyrazine derivatives
|
US20080027037A1
(en)
*
|
2000-04-28 |
2008-01-31 |
Tanabe Seiyaku Co., Ltd. |
Cyclic compounds
|
ES2559273T3
(es)
|
2000-05-08 |
2016-02-11 |
Janssen Pharmaceutica Nv |
Profármacos de pirimidinas que inhiben la replicación del VIH
|
CA2406562C
(en)
*
|
2000-05-08 |
2009-09-15 |
Janssen Pharmaceutica N.V. |
Hiv replication inhibiting pyrimidines and triazines
|
GB0016877D0
(en)
|
2000-07-11 |
2000-08-30 |
Astrazeneca Ab |
Chemical compounds
|
GB0021726D0
(en)
|
2000-09-05 |
2000-10-18 |
Astrazeneca Ab |
Chemical compounds
|
GB0103926D0
(en)
|
2001-02-17 |
2001-04-04 |
Astrazeneca Ab |
Chemical compounds
|
UA76977C2
(en)
|
2001-03-02 |
2006-10-16 |
Icos Corp |
Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers
|
GB0113041D0
(en)
|
2001-05-30 |
2001-07-18 |
Astrazeneca Ab |
Chemical compounds
|
US6939874B2
(en)
|
2001-08-22 |
2005-09-06 |
Amgen Inc. |
Substituted pyrimidinyl derivatives and methods of use
|
US7115617B2
(en)
|
2001-08-22 |
2006-10-03 |
Amgen Inc. |
Amino-substituted pyrimidinyl derivatives and methods of use
|
KR20050040814A
(ko)
*
|
2001-11-01 |
2005-05-03 |
얀센 파마슈티카 엔.브이. |
글리코겐 신타아제 키나제 3-베타 저해제로서의 아미드유도체
|
WO2003039557A1
(en)
*
|
2001-11-02 |
2003-05-15 |
The Regents Of The University Of California |
Methods and compositions for prevention and treatment of inflammatory disease, autoimmune disease, and transplant rejection
|
TWI329105B
(en)
|
2002-02-01 |
2010-08-21 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidinediamine compounds and their uses
|
RU2343148C2
(ru)
*
|
2002-02-01 |
2009-01-10 |
Райджел Фармасьютикалз, Инк |
Соединения 2,4-пиримидиндиаминов и их применение
|
GB0205688D0
(en)
|
2002-03-09 |
2002-04-24 |
Astrazeneca Ab |
Chemical compounds
|
GB0205690D0
(en)
|
2002-03-09 |
2002-04-24 |
Astrazeneca Ab |
Chemical compounds
|
GB0205693D0
(en)
|
2002-03-09 |
2002-04-24 |
Astrazeneca Ab |
Chemical compounds
|
JP2005524672A
(ja)
|
2002-03-09 |
2005-08-18 |
アストラゼネカ アクチボラグ |
Cdk阻害活性を有するイミダゾリル置換ピリミジン誘導体
|
GB0206215D0
(en)
*
|
2002-03-15 |
2002-05-01 |
Novartis Ag |
Organic compounds
|
US7176310B1
(en)
*
|
2002-04-09 |
2007-02-13 |
Ucb Sa |
Pyrimidinecarboxamide derivatives and their use as anti-inflammatory agents
|
WO2004002964A1
(ja)
*
|
2002-06-28 |
2004-01-08 |
Yamanouchi Pharmaceutical Co., Ltd. |
ジアミノピリミジンカルボキサミド誘導体
|
EP2316459B1
(de)
*
|
2002-07-29 |
2013-11-06 |
Rigel Pharmaceuticals, Inc. |
2,4-Pyrimidindiaminen zur Behandlung oder Vorbeugung von Autoimmunerkrankungen
|
IL166241A
(en)
*
|
2002-07-29 |
2011-12-29 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidinediamine compounds for use in the treatment of autoimmune diseases
|
AU2003250701A1
(en)
*
|
2002-07-31 |
2004-02-16 |
Wayne R. Danter |
Protein tyrosine kinase inhibitors
|
ATE380810T1
(de)
*
|
2002-10-09 |
2007-12-15 |
Critical Outcome Technologies |
Protein-tyrosine-kinase-inhibitoren
|
WO2004052364A1
(en)
*
|
2002-12-06 |
2004-06-24 |
The Trustees Of Boston University |
METHODS FOR SUSTAINING eNOS ACTIVITY
|
EP1572217B1
(de)
*
|
2002-12-12 |
2008-08-20 |
Nycomed GmbH |
Kombinationsarzneimittel aus r,r-formoterol und ciclesonide
|
WO2004054617A1
(ja)
*
|
2002-12-13 |
2004-07-01 |
Kyowa Hakko Kogyo Co., Ltd. |
中枢疾患の予防および/または治療剤
|
WO2004067516A1
(en)
*
|
2003-01-30 |
2004-08-12 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
2,4-diaminopyrimidine derivatives useful as inhibitors of pkc-theta
|
GB0305929D0
(en)
*
|
2003-03-14 |
2003-04-23 |
Novartis Ag |
Organic compounds
|
GB0311274D0
(en)
|
2003-05-16 |
2003-06-18 |
Astrazeneca Ab |
Chemical compounds
|
GB0311276D0
(en)
|
2003-05-16 |
2003-06-18 |
Astrazeneca Ab |
Chemical compounds
|
US7459460B2
(en)
*
|
2003-05-28 |
2008-12-02 |
Bristol-Myers Squibb Company |
Trisubstituted heteroaromatic compounds as calcium sensing receptor modulators
|
US7504396B2
(en)
*
|
2003-06-24 |
2009-03-17 |
Amgen Inc. |
Substituted heterocyclic compounds and methods of use
|
ES2421139T3
(es)
*
|
2003-07-30 |
2013-08-29 |
Rigel Pharmaceuticals, Inc. |
Compuestos de 2,4-pirimidindiamina para su uso en el tratamiento o la prevención de enfermedades autoinmunitarias
|
DK1663242T3
(da)
*
|
2003-08-07 |
2011-08-01 |
Rigel Pharmaceuticals Inc |
2,4-Pyrimidindiamin-forbindelser og anvendelse som antiproliferative midler
|
SG145749A1
(en)
*
|
2003-08-15 |
2008-09-29 |
Novartis Ag |
2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
|
PL1670482T5
(pl)
*
|
2003-09-16 |
2022-10-03 |
Covis Pharma Gmbh |
Zastosowanie cyklezonidu w leczeniu chorób układu oddechowego
|
TW200528101A
(en)
|
2004-02-03 |
2005-09-01 |
Astrazeneca Ab |
Chemical compounds
|
US8057815B2
(en)
*
|
2004-04-19 |
2011-11-15 |
Portola Pharmaceuticals, Inc. |
Methods of treatment with Syk inhibitors
|
JP2007533706A
(ja)
*
|
2004-04-20 |
2007-11-22 |
ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング |
喫煙患者における呼吸器疾患の治療のためのシクレソニドの使用
|
CA2571937A1
(en)
*
|
2004-07-08 |
2006-02-09 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Pyrimidine derivatives useful as inhibitors of pkc-theta
|
JP2008512429A
(ja)
*
|
2004-09-10 |
2008-04-24 |
ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング |
ロフルミラストとsykインヒビターとの組合せ物並びにその使用方法
|
AU2005281735A1
(en)
*
|
2004-09-10 |
2006-03-16 |
Nycomed Gmbh |
Ciclesonide and syk inhibitor combination and methods of use thereof
|
ES2380550T3
(es)
*
|
2004-11-24 |
2012-05-16 |
Rigel Pharmaceuticals, Inc. |
Compuestos de espiro-2,4-pirimidindiamina y sus usos
|
EP1828183A1
(de)
*
|
2004-12-17 |
2007-09-05 |
AstraZeneca AB |
4-(4-(imidazol-4-yl)pyrimidin-2-ylamino)benzamide als cdk-inhibitoren
|
ES2337496T3
(es)
|
2005-01-19 |
2010-04-26 |
Rigel Pharmaceuticals, Inc. |
Profarmacos de compuestos de 2,4-pirimidindiamina y sus usos.
|
EP1856075A1
(de)
*
|
2005-01-25 |
2007-11-21 |
Epix Delaware, Inc. |
Substituierte arylaminverbindungen und ihre verwendung als 5-ht6-modulatoren
|
TW200722087A
(en)
*
|
2005-03-30 |
2007-06-16 |
Astion Dev As |
Treatment of dermatological diseases and pruritus
|
JP2008540436A
(ja)
*
|
2005-05-03 |
2008-11-20 |
ライジェル ファーマシューティカルズ, インコーポレイテッド |
Jakキナーゼインヒビターおよびそれらの使用
|
WO2007028445A1
(en)
*
|
2005-07-15 |
2007-03-15 |
Glaxo Group Limited |
6-indolyl-4-yl-amino-5-halogeno-2-pyrimidinyl-amino derivatives
|
TW200740805A
(en)
*
|
2005-07-15 |
2007-11-01 |
Glaxo Group Ltd |
Novel compounds
|
EP2301928A1
(de)
*
|
2005-07-30 |
2011-03-30 |
AstraZeneca AB |
Imidazolylpyrimidinverbindungen zur Verwendung bei der Behandlung von proliferativen Erkrankungen
|
CA2623374A1
(en)
|
2005-09-30 |
2007-04-05 |
Astrazeneca Ab |
Imidazo [1,2-a] pyridine having anti-cell-proliferation activity
|
US8604042B2
(en)
*
|
2005-11-01 |
2013-12-10 |
Targegen, Inc. |
Bi-aryl meta-pyrimidine inhibitors of kinases
|
NZ592990A
(en)
*
|
2005-11-01 |
2013-01-25 |
Targegen Inc |
Bi-aryl meta-pyrimidine inhibitors of kinases
|
US8133900B2
(en)
|
2005-11-01 |
2012-03-13 |
Targegen, Inc. |
Use of bi-aryl meta-pyrimidine inhibitors of kinases
|
TW200811169A
(en)
*
|
2006-05-26 |
2008-03-01 |
Astrazeneca Ab |
Chemical compounds
|
AU2007276369A1
(en)
*
|
2006-07-21 |
2008-01-24 |
Novartis Ag |
2, 4 -di (arylaminio) -pyrimidine-5-carboxamide compounds as JAK kinases inhibitors
|
ES2524009T3
(es)
|
2006-12-08 |
2014-12-03 |
Irm Llc |
Compuestos y composiciones como inhibidores de la proteína quinasa
|
WO2008083491A1
(en)
|
2007-01-11 |
2008-07-17 |
Critical Outcome Technologies Inc. |
Compounds and method for treatment of cancer
|
JP2010518064A
(ja)
*
|
2007-02-12 |
2010-05-27 |
メルク・シャープ・エンド・ドーム・コーポレイション |
Adおよび関連状態の治療のためのピペラジン誘導体
|
US8466151B2
(en)
*
|
2007-12-26 |
2013-06-18 |
Critical Outcome Technologies, Inc. |
Compounds and method for treatment of cancer
|
US10131904B2
(en)
|
2008-02-11 |
2018-11-20 |
Rxi Pharmaceuticals Corporation |
Modified RNAi polynucleotides and uses thereof
|
KR101773313B1
(ko)
*
|
2008-04-16 |
2017-08-31 |
포톨라 파마슈티컬스, 인코포레이티드 |
syk 또는 JAK 키나제 억제제로서의 2,6-디아미노-피리미딘-5-일-카르복스아미드
|
EA024109B1
(ru)
*
|
2008-04-16 |
2016-08-31 |
Портола Фармасьютиклз, Инк. |
Ингибиторы протеинкиназ
|
US8138339B2
(en)
|
2008-04-16 |
2012-03-20 |
Portola Pharmaceuticals, Inc. |
Inhibitors of protein kinases
|
ES2546502T3
(es)
|
2008-04-16 |
2015-09-24 |
Portola Pharmaceuticals, Inc. |
2,6-Diamino-pirimidin-5-il-carboxamidas como inhibidores de syk o JAK quinasas
|
BRPI0910560B8
(pt)
*
|
2008-04-16 |
2023-03-21 |
Portola Pharm Inc |
Compostos de 2,6-diamino-pirimidin-5-il-carboxamidas como inibidores de syk ou jak quinases, composição, método para inibição de syk, jak quinase ou um sinal de via de transdução mediada ao menos por atividade de syk ou jak, e kit
|
LT2300013T
(lt)
|
2008-05-21 |
2017-12-27 |
Ariad Pharmaceuticals, Inc. |
Fosforo dariniai kaip kinazių inhibitoriai
|
US9273077B2
(en)
|
2008-05-21 |
2016-03-01 |
Ariad Pharmaceuticals, Inc. |
Phosphorus derivatives as kinase inhibitors
|
CN102083800A
(zh)
|
2008-06-27 |
2011-06-01 |
阿维拉制药公司 |
杂芳基化合物和其用途
|
US11351168B1
(en)
|
2008-06-27 |
2022-06-07 |
Celgene Car Llc |
2,4-disubstituted pyrimidines useful as kinase inhibitors
|
US8338439B2
(en)
|
2008-06-27 |
2012-12-25 |
Celgene Avilomics Research, Inc. |
2,4-disubstituted pyrimidines useful as kinase inhibitors
|
CA2999321A1
(en)
|
2008-07-17 |
2010-01-21 |
Critical Outcome Technologies Inc. |
Thiosemicarbazone inhibitor compounds and cancer treatment methods
|
WO2010008582A2
(en)
|
2008-07-18 |
2010-01-21 |
Rxi Pharmaceuticals Corporation |
Phagocytic cell drug delivery system
|
JP2012502991A
(ja)
|
2008-09-22 |
2012-02-02 |
アールエックスアイ ファーマシューティカルズ コーポレーション |
皮膚適用におけるrna干渉
|
WO2010059226A2
(en)
|
2008-11-19 |
2010-05-27 |
Rxi Pharmaceuticals Corporation |
Inhibition of map4k4 through rnai
|
EP2361902A4
(de)
*
|
2008-11-21 |
2012-04-25 |
Astellas Pharma Inc |
4,6-diaminonicotinsäureamidverbindung
|
US9493774B2
(en)
|
2009-01-05 |
2016-11-15 |
Rxi Pharmaceuticals Corporation |
Inhibition of PCSK9 through RNAi
|
CA2749403A1
(en)
*
|
2009-01-13 |
2010-09-02 |
Glaxo Group Limited |
Pyrimidinecarboxamide derivatives as inhibitors of syk kinase
|
WO2010090762A1
(en)
|
2009-02-04 |
2010-08-12 |
Rxi Pharmaceuticals Corporation |
Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
|
US9908884B2
(en)
|
2009-05-05 |
2018-03-06 |
Dana-Farber Cancer Institute, Inc. |
EGFR inhibitors and methods of treating disorders
|
WO2010129802A1
(en)
*
|
2009-05-06 |
2010-11-11 |
Portola Pharmaceuticals, Inc. |
Inhibitors of jak
|
US8586751B2
(en)
|
2009-06-12 |
2013-11-19 |
Bristol-Myers Squibb Company |
Nicotinamide compounds useful as kinase modulators
|
TW201105669A
(en)
*
|
2009-07-30 |
2011-02-16 |
Irm Llc |
Compounds and compositions as Syk kinase inhibitors
|
US9573907B2
(en)
*
|
2009-11-02 |
2017-02-21 |
Snu R&Db Foundation |
2, 4-pyrimidine derivatives and use thereof
|
WO2011065800A2
(ko)
*
|
2009-11-30 |
2011-06-03 |
주식회사 오스코텍 |
피리미딘 유도체, 이의 제조방법 및 이를 함유하는 약학적 조성물
|
UA107100C2
(xx)
|
2009-12-23 |
2014-11-25 |
|
Конденсовані гетероароматичні піролідинони як інгібітори syk
|
ES2535116T3
(es)
|
2010-03-04 |
2015-05-05 |
Cellzome Limited |
Derivados de urea sustituida con morfolino como inhibidores de mtor
|
WO2011119852A1
(en)
|
2010-03-24 |
2011-09-29 |
Rxi Pharmaceuticals Corporation |
Reduced size self-delivering rnai compounds
|
WO2011119871A1
(en)
|
2010-03-24 |
2011-09-29 |
Rxi Phrmaceuticals Corporation |
Rna interference in ocular indications
|
BR112012024049A2
(pt)
|
2010-03-24 |
2017-03-01 |
Rxi Pharmaceuticals Corp |
interferência de rna em indicações dérmicas e fibróticas
|
WO2011120153A1
(en)
|
2010-04-01 |
2011-10-06 |
Critical Outcome Technologies Inc. |
Compounds and method for treatment of hiv
|
EP3144298A1
(de)
|
2010-08-10 |
2017-03-22 |
Celgene Avilomics Research, Inc. |
Besylatsalz aus einem btk-hemmer
|
US8580805B2
(en)
*
|
2010-08-31 |
2013-11-12 |
Hubert Maehr |
Pyrimidine carboxamide derivatives
|
EP2635285B1
(de)
|
2010-11-01 |
2017-05-03 |
Celgene Avilomics Research, Inc. |
Heteroarylverbindungen und ihre verwendung
|
RU2644151C2
(ru)
|
2010-11-01 |
2018-02-08 |
Селджен Авиломикс Рисерч, Инк. |
Гетероциклические соединения и их применение
|
AU2010363329A1
(en)
|
2010-11-07 |
2013-05-09 |
Targegen, Inc. |
Compositions and methods for treating myelofibrosis
|
JP5957003B2
(ja)
|
2010-11-10 |
2016-07-27 |
セルジーン アヴィロミクス リサーチ, インコーポレイテッド |
変異体選択的egfr阻害剤およびその使用
|
GB201104153D0
(en)
|
2011-03-11 |
2011-04-27 |
Glaxo Group Ltd |
Novel compounds
|
EP4328223A2
(de)
*
|
2011-04-22 |
2024-02-28 |
Signal Pharmaceuticals, LLC |
Substituierte diaminocarboxamid- und diaminocarbonitrilpyrimidine, zusammensetzungen davon und behandlungsverfahren damit
|
AU2016244228B2
(en)
*
|
2011-04-22 |
2019-02-21 |
Signal Pharmaceuticals, Llc |
Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith
|
WO2012151561A1
(en)
|
2011-05-04 |
2012-11-08 |
Ariad Pharmaceuticals, Inc. |
Compounds for inhibiting cell proliferation in egfr-driven cancers
|
AU2012253885A1
(en)
|
2011-05-10 |
2013-10-31 |
Merck Sharp & Dohme Corp. |
Aminopyrimidines as Syk inhibitors
|
US9145391B2
(en)
|
2011-05-10 |
2015-09-29 |
Merck Sharp & Dohme Corp. |
Bipyridylaminopyridines as Syk inhibitors
|
JP2014513687A
(ja)
|
2011-05-10 |
2014-06-05 |
メルク・シャープ・アンド・ドーム・コーポレーション |
Syk阻害薬としてのピリジルアミノピリジン
|
EP2723739B1
(de)
|
2011-06-22 |
2016-08-24 |
Takeda Pharmaceutical Company Limited |
Substituierte 6-aza-isoindolin-1-on-derivate
|
EP2736901A1
(de)
*
|
2011-07-28 |
2014-06-04 |
Cellzome Limited |
Heterocyclische pyrimidinanaloga als jak-inhibitoren
|
RU2564419C1
(ru)
*
|
2011-07-28 |
2015-09-27 |
Целльзом Лимитид |
Гетероциклические аналоги пиримидина в качестве ингибиторов jak
|
RU2616619C2
(ru)
|
2011-09-21 |
2017-04-18 |
Селлзоум Лимитед |
Морфолино-замещенные производные мочевины или карбамата в качестве ингибиторов mtor
|
US9145414B2
(en)
|
2011-09-30 |
2015-09-29 |
Taiho Pharmaceutical Co., Ltd. |
1,2,4-triazine-6-carboxamide derivative
|
WO2013052394A1
(en)
|
2011-10-05 |
2013-04-11 |
Merck Sharp & Dohme Corp. |
2-pyridyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors
|
EP2763975B1
(de)
|
2011-10-05 |
2016-04-06 |
Merck Sharp & Dohme Corp. |
3-pyridyl-carboxamidhaltige milztyrosinkinase-(syk)-hemmer
|
EP2763974B1
(de)
|
2011-10-05 |
2016-09-14 |
Merck Sharp & Dohme Corp. |
Phenylcarboxamidhaltige milztyrosinkinase (syk) hemmer
|
AU2012320465B2
(en)
|
2011-10-07 |
2016-03-03 |
Cellzome Limited |
Morpholino substituted bicyclic pyrimidine urea or carbamate derivatives as mTOR inhibitors
|
AR088570A1
(es)
|
2011-10-28 |
2014-06-18 |
Celgene Avilomics Res Inc |
Metodos para tratar una enfermedad o trastorno relacionado con la tirosina quinasa de bruton
|
IN2014CN04065A
(de)
|
2011-11-23 |
2015-09-04 |
Portola Pharm Inc |
|
EP2782580A4
(de)
*
|
2011-11-23 |
2015-10-07 |
Portola Pharm Inc |
Selektive kinasehemmer
|
TWI546287B
(zh)
*
|
2011-12-28 |
2016-08-21 |
富士軟片股份有限公司 |
新穎菸鹼醯胺衍生物或其鹽
|
RU2711077C9
(ru)
|
2012-03-15 |
2020-08-11 |
Селджен Кар Ллс |
Соли ингибитора киназы рецептора эпидермального фактора роста
|
EP2825041B1
(de)
|
2012-03-15 |
2021-04-21 |
Celgene CAR LLC |
Feste formen eines epidermalen wachstumsfaktor-rezeptor-kinase-hemmers
|
KR20150010716A
(ko)
|
2012-03-23 |
2015-01-28 |
더 유니버시티 오브 퀸스랜드 |
면역조절제 및 이의 용도
|
JP6469567B2
(ja)
|
2012-05-05 |
2019-02-13 |
アリアド・ファーマシューティカルズ・インコーポレイテッド |
Egfr発動性がんの細胞増殖阻害用化合物
|
UY34807A
(es)
|
2012-05-16 |
2013-12-31 |
Novartis Ag |
Derivados monocíclicos de heteroarilcicloalquil- diamina
|
WO2013192128A1
(en)
|
2012-06-20 |
2013-12-27 |
Merck Sharp & Dohme Corp. |
Imidazolyl analogs as syk inhibitors
|
WO2013192088A1
(en)
|
2012-06-22 |
2013-12-27 |
Merck Sharp & Dohme Corp. |
SUBSTITUTED DIAZINE AND TRIAZINE SPLEEN TYROSINE KINASE (Syk) INHIBITORS
|
EP2863916B1
(de)
|
2012-06-22 |
2018-07-18 |
Merck Sharp & Dohme Corp. |
Substituierte pyridin-milz-tyrosinkinaseinhibitoren
|
WO2014031438A2
(en)
*
|
2012-08-20 |
2014-02-27 |
Merck Sharp & Dohme Corp. |
SUBSTITUTED PHENYL SPLEEN TYROSINE KINASE (Syk) INHIBITORS
|
EP2900665B1
(de)
|
2012-09-28 |
2018-01-03 |
Merck Sharp & Dohme Corp. |
Triazolylderivate als syk-hemmer
|
CA2883534A1
(en)
*
|
2012-10-19 |
2014-04-24 |
F. Hoffmann-La Roche Ag |
Inhibitors of syk
|
US9624210B2
(en)
|
2012-12-12 |
2017-04-18 |
Merck Sharp & Dohme Corp. |
Amino-pyrimidine-containing spleen tyrosine kinase (Syk) inhibitors
|
US9598405B2
(en)
|
2012-12-21 |
2017-03-21 |
Merck Sharp & Dohme Corp. |
Thiazole-substituted aminopyridines as spleen tyrosine kinase inhibitors
|
EP2935226A4
(de)
|
2012-12-21 |
2016-11-02 |
Celgene Avilomics Res Inc |
Heteroarylverbindungen und verwendungen davon
|
WO2014111031A1
(zh)
*
|
2013-01-17 |
2014-07-24 |
四川恒康发展有限责任公司 |
三嗪化合物、其药用盐、异构体或水合物及其药物组合物
|
US9561228B2
(en)
|
2013-02-08 |
2017-02-07 |
Celgene Avilomics Research, Inc. |
ERK inhibitors and uses thereof
|
US9611283B1
(en)
|
2013-04-10 |
2017-04-04 |
Ariad Pharmaceuticals, Inc. |
Methods for inhibiting cell proliferation in ALK-driven cancers
|
US9745295B2
(en)
|
2013-04-26 |
2017-08-29 |
Merck Sharp & Dohme Corp. |
Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
|
EP2988749B1
(de)
|
2013-04-26 |
2019-08-14 |
Merck Sharp & Dohme Corp. |
Thiazolsubstituierte aminopyridine als milztyrosinkinasehemmer
|
US9492471B2
(en)
|
2013-08-27 |
2016-11-15 |
Celgene Avilomics Research, Inc. |
Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
|
RU2744194C2
(ru)
|
2013-12-02 |
2021-03-03 |
Фио Фармасьютикалс Корп |
Иммунотерапия рака
|
KR20160110370A
(ko)
|
2013-12-04 |
2016-09-21 |
알엑스아이 파마슈티칼스 코포레이션 |
화학적으로 변형된 올리고뉴클레오티드를 사용한 상처 치유의 치료 방법
|
AU2014360446A1
(en)
|
2013-12-05 |
2016-06-09 |
Pharmacyclics, Llc |
Inhibitors of Bruton's tyrosine kinase
|
US9415049B2
(en)
|
2013-12-20 |
2016-08-16 |
Celgene Avilomics Research, Inc. |
Heteroaryl compounds and uses thereof
|
EP3083559B1
(de)
|
2013-12-20 |
2021-03-10 |
Merck Sharp & Dohme Corp. |
Thiazolsubstituierte aminoheteroaryle als milztyrosinkinasehemmer
|
WO2015094997A1
(en)
|
2013-12-20 |
2015-06-25 |
Merck Sharp & Dohme Corp. |
Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
|
WO2015095444A1
(en)
|
2013-12-20 |
2015-06-25 |
Merck Sharp & Dohme Corp. |
Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
|
NZ715903A
(en)
|
2014-01-30 |
2017-06-30 |
Signal Pharm Llc |
Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use
|
US9775839B2
(en)
|
2014-03-13 |
2017-10-03 |
Merck Sharp & Dohme Corp. |
2-pyrazine carboxamides as spleen tyrosine kinase inhibitors
|
EP3134439B1
(de)
|
2014-04-21 |
2018-12-26 |
Millennium Pharmaceuticals, Inc. |
Anti-psyk-antikörpermoleküle und verwendung davon für eine auf syk abzielende therapie
|
CA2947270A1
(en)
|
2014-04-28 |
2015-11-05 |
Rxi Pharmaceuticals Corporation |
Methods for treating cancer using nucleic acids targeting mdm2 or mycn
|
JP2017514908A
(ja)
|
2014-05-01 |
2017-06-08 |
アールエックスアイ ファーマシューティカルズ コーポレーション |
核酸分子を利用する目の前部における障害の処置のための方法
|
EP3179858B1
(de)
|
2014-08-13 |
2019-05-15 |
Celgene Car Llc |
Formen und zusammensetzungen eines erk-inhibitors
|
US10900039B2
(en)
|
2014-09-05 |
2021-01-26 |
Phio Pharmaceuticals Corp. |
Methods for treating aging and skin disorders using nucleic acids targeting Tyr or MMP1
|
JP6903577B2
(ja)
|
2014-12-16 |
2021-07-14 |
シグナル ファーマシューティカルズ,エルエルシー |
皮膚におけるc−Jun N末端キナーゼの阻害の測定方法
|
MX2017007883A
(es)
|
2014-12-16 |
2017-09-05 |
Signal Pharm Llc |
Formulaciones de 2-(ter-butilamino)-4-((1r,3r,4r)-3-hdroxi-4-metil ciclohexilamino)-pirimidina-5-carboxamida.
|
EP3250557A4
(de)
|
2015-01-29 |
2018-06-20 |
Signal Pharmaceuticals, LLC |
Isotopologe von 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidin-5-carboxamid
|
WO2016168444A1
(en)
*
|
2015-04-14 |
2016-10-20 |
Purdue Research Foundation Office Of Technology Commercialization |
Methods for treating hemolytic diseases and sickle cell disease
|
KR102613106B1
(ko)
|
2015-05-29 |
2023-12-12 |
포톨라 파마슈티컬스, 인코포레이티드 |
B―세포 악성종양의 치료를 위한 세르둘라티닙
|
WO2017007825A1
(en)
|
2015-07-06 |
2017-01-12 |
Rxi Pharmaceuticals Corporation |
Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
|
CN108135923B
(zh)
|
2015-07-06 |
2021-03-02 |
菲奥医药公司 |
靶向超氧化物歧化酶1(sod1)的核酸分子
|
MX2020001720A
(es)
|
2015-07-24 |
2021-08-13 |
Celgene Corp |
Metodos de sintesis de clorhidrato de (1r,2r,5r)-5-amino-2-metilci clohexanol e intermedios utiles en este.
|
JP2018531037A
(ja)
|
2015-10-19 |
2018-10-25 |
アールエックスアイ ファーマシューティカルズ コーポレーション |
長い非コードrnaを標的とする減少したサイズの自己送達型核酸化合物
|
ES2959692T3
(es)
|
2015-12-04 |
2024-02-27 |
Alexion Pharma Inc |
Cerdulatinib y venetoclax para tratar linfoma no Hodgkin
|
WO2018002311A1
(en)
|
2016-06-30 |
2018-01-04 |
Siess Wolfgang |
Treatment and prevention of atherothrombosis by inhibition of syk kinase
|
GB201807845D0
(en)
*
|
2018-05-15 |
2018-06-27 |
Univ Manchester |
Kinase Inhibitors
|
WO2021092464A2
(en)
|
2019-11-08 |
2021-05-14 |
Phio Pharmaceuticals Corp. |
Chemically modified oligonucleotides targeting bromodomain containing protein 4 (brd4) for immunotherapy
|
US20230089478A1
(en)
|
2019-12-31 |
2023-03-23 |
Phio Pharmaceuticals Corp. |
Chemically modified oligonucleotides with improved systemic delivery
|
WO2023015264A1
(en)
|
2021-08-04 |
2023-02-09 |
Phio Pharmaceuticals Corp. |
Immunotherapy of cancer utilizing natural killer cells treated with chemically modified oligonucleotides
|
KR20240041973A
(ko)
|
2021-08-04 |
2024-04-01 |
피오 파마슈티칼스 코프. |
화학적으로 변형된 올리고뉴클레오티드
|